ES2966055T3 - Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC - Google Patents
Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC Download PDFInfo
- Publication number
- ES2966055T3 ES2966055T3 ES19797472T ES19797472T ES2966055T3 ES 2966055 T3 ES2966055 T3 ES 2966055T3 ES 19797472 T ES19797472 T ES 19797472T ES 19797472 T ES19797472 T ES 19797472T ES 2966055 T3 ES2966055 T3 ES 2966055T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745109P | 2018-10-12 | 2018-10-12 | |
| PCT/US2019/055926 WO2020077255A1 (en) | 2018-10-12 | 2019-10-11 | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2966055T3 true ES2966055T3 (es) | 2024-04-18 |
Family
ID=68425315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19797472T Active ES2966055T3 (es) | 2018-10-12 | 2019-10-11 | Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11634453B2 (enExample) |
| EP (2) | EP4321519B1 (enExample) |
| JP (2) | JP7671244B2 (enExample) |
| CN (2) | CN121045302A (enExample) |
| AR (1) | AR116695A1 (enExample) |
| AU (2) | AU2019357040B2 (enExample) |
| BR (1) | BR112021009428A2 (enExample) |
| CA (1) | CA3115805A1 (enExample) |
| DK (1) | DK3864022T3 (enExample) |
| ES (1) | ES2966055T3 (enExample) |
| IL (1) | IL282183A (enExample) |
| MX (2) | MX2021004159A (enExample) |
| TW (2) | TWI835884B (enExample) |
| WO (1) | WO2020077255A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| EP4321519B1 (en) * | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| ES2296594T3 (es) * | 1994-02-14 | 2008-05-01 | Euro-Celtique S.A. | Androstanos y pregnanos para la modulacion alosterica del receptor de gaba. |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| NZ298567A (en) | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| HUE039057T2 (hu) | 2012-12-18 | 2018-12-28 | Univ Washington | Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| MX2020006599A (es) | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| BR112020012761A2 (pt) | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| EP4321519B1 (en) * | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| JP7754725B2 (ja) | 2019-06-27 | 2025-10-15 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を治療するための組成物及び方法 |
| WO2021188778A2 (en) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20230250129A1 (en) | 2020-06-24 | 2023-08-10 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
-
2019
- 2019-10-11 EP EP23197779.4A patent/EP4321519B1/en active Active
- 2019-10-11 BR BR112021009428-8A patent/BR112021009428A2/pt unknown
- 2019-10-11 JP JP2021519712A patent/JP7671244B2/ja active Active
- 2019-10-11 DK DK19797472.8T patent/DK3864022T3/da active
- 2019-10-11 CA CA3115805A patent/CA3115805A1/en active Pending
- 2019-10-11 US US17/284,206 patent/US11634453B2/en active Active
- 2019-10-11 MX MX2021004159A patent/MX2021004159A/es unknown
- 2019-10-11 AR ARP190102913A patent/AR116695A1/es unknown
- 2019-10-11 CN CN202511082220.8A patent/CN121045302A/zh active Pending
- 2019-10-11 AU AU2019357040A patent/AU2019357040B2/en active Active
- 2019-10-11 WO PCT/US2019/055926 patent/WO2020077255A1/en not_active Ceased
- 2019-10-11 CN CN201980079330.5A patent/CN113166193B/zh active Active
- 2019-10-11 ES ES19797472T patent/ES2966055T3/es active Active
- 2019-10-11 EP EP19797472.8A patent/EP3864022B1/en active Active
- 2019-10-14 TW TW108136955A patent/TWI835884B/zh active
- 2019-10-14 TW TW113106814A patent/TWI886813B/zh active
-
2021
- 2021-04-08 IL IL282183A patent/IL282183A/en unknown
- 2021-04-09 MX MX2024011494A patent/MX2024011494A/es unknown
-
2023
- 2023-02-21 US US18/171,798 patent/US20240376144A9/en active Pending
-
2024
- 2024-02-14 JP JP2024020461A patent/JP2024040444A/ja active Pending
-
2025
- 2025-01-22 AU AU2025200422A patent/AU2025200422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011494A (es) | 2024-09-26 |
| WO2020077255A1 (en) | 2020-04-16 |
| EP3864022A1 (en) | 2021-08-18 |
| US20240376144A9 (en) | 2024-11-14 |
| JP7671244B2 (ja) | 2025-05-01 |
| JP2022504607A (ja) | 2022-01-13 |
| EP4321519A3 (en) | 2024-05-01 |
| MX2021004159A (es) | 2021-09-08 |
| AU2025200422A1 (en) | 2025-02-13 |
| US11634453B2 (en) | 2023-04-25 |
| TW202027753A (zh) | 2020-08-01 |
| AU2019357040A1 (en) | 2021-05-20 |
| IL282183A (en) | 2021-05-31 |
| CN121045302A (zh) | 2025-12-02 |
| EP3864022B1 (en) | 2023-09-20 |
| US20210340172A1 (en) | 2021-11-04 |
| JP2024040444A (ja) | 2024-03-25 |
| DK3864022T3 (da) | 2023-12-18 |
| EP4321519B1 (en) | 2026-04-08 |
| TW202448479A (zh) | 2024-12-16 |
| AU2019357040B2 (en) | 2025-03-27 |
| AR116695A1 (es) | 2021-06-02 |
| EP4321519A2 (en) | 2024-02-14 |
| BR112021009428A2 (pt) | 2021-08-31 |
| TWI835884B (zh) | 2024-03-21 |
| US20240051987A1 (en) | 2024-02-15 |
| TWI886813B (zh) | 2025-06-11 |
| CN113166193B (zh) | 2025-08-19 |
| CN113166193A (zh) | 2021-07-23 |
| CA3115805A1 (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2966055T3 (es) | Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC | |
| ES2992037T3 (es) | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización | |
| ES2991092T3 (es) | Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC | |
| US11147877B2 (en) | Compositions and methods for treating CNS disorders | |
| ES2935476T3 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| US12421275B2 (en) | Compositions and methods for treating CNS disorders | |
| ES2965214T3 (es) | Esteroides neuroactivos sustituidos en C17, C20 y C21 y sus procedimientos de utilización | |
| ES3039267T3 (en) | 9(11)-unsaturated neuroactive steroids and their methods of use | |
| BR112021012242A2 (pt) | Esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida e composições destes | |
| RU2796006C2 (ru) | Нейроактивные стероиды, замещенные в положении 10 циклической группой, для использования при лечении расстройств цнс | |
| HK40106568A (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| HK40059417A (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| HK40059417B (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| BR122024013785A2 (pt) | Compostos esteroides neuroativos, composição farmacêutica e seus usos | |
| BR122024007325A2 (pt) | Compostos esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida, suas composições farmacêuticas e seus usos |